MacroGenics, Inc. (NASDAQ:MGNX) – Investment analysts at Leerink Swann boosted their FY2017 earnings per share estimates for shares of MacroGenics in a report released on Wednesday. Leerink Swann analyst M. Schmidt now expects that the biopharmaceutical company will post earnings per share of ($4.69) for the year, up from their prior estimate of ($4.71). Leerink Swann also issued estimates for MacroGenics’ Q4 2017 earnings at ($1.23) EPS and FY2018 earnings at ($4.76) EPS.

Several other equities research analysts also recently issued reports on MGNX. Morgan Stanley cut their price target on MacroGenics from $24.00 to $22.00 and set an “equal weight” rating for the company in a report on Monday, May 8th. Zacks Investment Research raised MacroGenics from a “sell” rating to a “hold” rating and set a $19.00 price target for the company in a report on Tuesday, July 18th. BidaskClub downgraded MacroGenics from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Cowen and Company reaffirmed a “buy” rating on shares of MacroGenics in a report on Friday, August 4th. Finally, ValuEngine downgraded MacroGenics from a “sell” rating to a “strong sell” rating in a report on Thursday, August 3rd. Three analysts have rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company. MacroGenics presently has an average rating of “Hold” and an average price target of $32.30.

WARNING: “MacroGenics, Inc. Forecasted to Post FY2017 Earnings of ($4.69) Per Share (NASDAQ:MGNX)” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/09/macrogenics-inc-forecasted-to-post-fy2017-earnings-of-4-69-per-share-nasdaqmgnx.html.

MacroGenics (MGNX) traded down 2.299% during trading on Monday, hitting $16.365. 58,251 shares of the stock were exchanged. The stock’s market cap is $602.20 million. MacroGenics has a 1-year low of $14.36 and a 1-year high of $33.30. The firm’s 50 day moving average price is $17.63 and its 200-day moving average price is $18.82.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.05) by $0.09. MacroGenics had a negative net margin of 1,216.51% and a negative return on equity of 56.81%. The firm had revenue of $1.70 million during the quarter, compared to the consensus estimate of $15.82 million. During the same period in the prior year, the business earned $1.12 EPS. The company’s revenue for the quarter was down 97.9% compared to the same quarter last year.

Several hedge funds and other institutional investors have recently modified their holdings of MGNX. Russell Investments Group Ltd. bought a new position in shares of MacroGenics during the second quarter worth approximately $133,000. Legal & General Group Plc raised its stake in MacroGenics by 4.3% in the second quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 328 shares during the period. SG Americas Securities LLC raised its stake in MacroGenics by 92.2% in the second quarter. SG Americas Securities LLC now owns 10,812 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 5,187 shares during the period. American International Group Inc. raised its stake in MacroGenics by 7.1% in the first quarter. American International Group Inc. now owns 19,632 shares of the biopharmaceutical company’s stock valued at $365,000 after buying an additional 1,300 shares during the period. Finally, Stifel Financial Corp raised its stake in MacroGenics by 7.8% in the first quarter. Stifel Financial Corp now owns 20,155 shares of the biopharmaceutical company’s stock valued at $370,000 after buying an additional 1,450 shares during the period. Institutional investors own 82.34% of the company’s stock.

In related news, SVP Jon Marc Wigginton sold 5,000 shares of the firm’s stock in a transaction on Monday, June 5th. The stock was sold at an average price of $20.00, for a total value of $100,000.00. Following the transaction, the senior vice president now owns 35,000 shares in the company, valued at $700,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.30% of the stock is currently owned by company insiders.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Earnings History and Estimates for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.